Pharmacokinetic Drug‐Drug Interaction Study of Omecamtiv Mecarbil With Amiodarone and Digoxin in Healthy Subjects

Omecamtiv mecarbil (OM), a novel cardiac myosin activator, is being evaluated for the treatment of heart failure with reduced ejection fraction. In vitro studies demonstrate OM as a substrate and inhibitor of P‐glycoprotein (P‐gp), which can result in drug‐drug interactions. Two phase 1, open‐label...

Descripción completa

Detalles Bibliográficos
Autores principales: Trivedi, Ashit, Sohn, Winnie, Hsu, Cheng‐Pang, Jafarinasabian, Pegah, Zhang, Hanze, Hutton, Shauna, Flach, Stephen, Abbasi, Siddique, Dutta, Sandeep, Lee, Edward
Formato: Online Artículo Texto
Lenguaje:English
Publicado: John Wiley and Sons Inc. 2021
Materias:
Articles
Acceso en línea:https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293137/
https://www.ncbi.nlm.nih.gov/pubmed/34634185
http://dx.doi.org/10.1002/cpdd.1028

Internet

https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9293137/
https://www.ncbi.nlm.nih.gov/pubmed/34634185
http://dx.doi.org/10.1002/cpdd.1028

Ejemplares similares